Effects of vitamin D supplements on frequency of CD4+ T-cell subsets in women with Hashimoto's thyroiditis: a double-blind placebo-controlled study.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Vitamin D is a modulator of immune functions.

Who Took Part

The study group was 48 patients.

By PubMed's age tags, the people studied were adults and middle-aged adults, women only.

Totally, 48 female patients with HT disease were introduced to the study by endocrinologists.

Eventually, 17 of the 24 patients in each group finished the study.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The patients were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

Some patients received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

Before and after supplementation, frequencies of Th1, Th17, Th2 and Tr1 cells and mean fluorescent intensity (MFI) of the associated cytokines, including IFN-γ, IL-17, IL-4 and IL-10, were assessed using flow cytometry.

Furthermore, gene expression of IL-10 was assessed using real-time PCR.

What Was Measured

The subject headings attached to it are Autoantibodies, CD4 Lymphocyte Count, Calcifediol, Cytokines, Dietary Supplements, Hashimoto Disease and Iodide Peroxidase.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 48 patients.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (European journal of clinical nutrition), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.